Goldman upgrades the Life Sciences Tools & Diagnostics sector to Attractive, but some...
Goldman upgrades the Life Sciences Tools & Diagnostics sector to Attractive, but some individual names suffered as Mettler Toledo (MTD -2%) and Sigma-Aldrich (SIAL -1.1%) catch downgrades to Neutral from Buy. SIAL has "few levers to drive EBIT [as] long-term organic growth guidance of 4-6% is too high." Quest Diagnostics (DGX +3.5%) and LabCorp (LH +2%) are upgraded to Buy and Neutral respectively on the former's "untapped capital allocation potential and margin expansion" and the latter's ability to manage pricing pressure.
From other sites
at CNBC.com (Oct 17, 2014)
at CNBC.com (Jul 23, 2014)
at CNBC.com (Jul 22, 2014)
at CNBC.com (Jul 21, 2014)
at CNBC.com (Oct 12, 2010)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs